[go: up one dir, main page]

BRPI1008885A2 - anticorpo, método para a produção de um anticorpo, uso do anticorpo, método para a produção de polipeptídeo de neurotoxina processado, métoro para a produção de um medicamento e composição - Google Patents

anticorpo, método para a produção de um anticorpo, uso do anticorpo, método para a produção de polipeptídeo de neurotoxina processado, métoro para a produção de um medicamento e composição

Info

Publication number
BRPI1008885A2
BRPI1008885A2 BRPI1008885A BRPI1008885A BRPI1008885A2 BR PI1008885 A2 BRPI1008885 A2 BR PI1008885A2 BR PI1008885 A BRPI1008885 A BR PI1008885A BR PI1008885 A BRPI1008885 A BR PI1008885A BR PI1008885 A2 BRPI1008885 A2 BR PI1008885A2
Authority
BR
Brazil
Prior art keywords
antibody
producing
medicament
composition
neurotoxin polypeptide
Prior art date
Application number
BRPI1008885A
Other languages
English (en)
Inventor
Cornelia Brünn
Harold V Taylor
Josef Friedrich
Karl-Heinz Eisele
Michael Pfeil
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of BRPI1008885A2 publication Critical patent/BRPI1008885A2/pt
Publication of BRPI1008885B1 publication Critical patent/BRPI1008885B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI1008885-7A 2009-02-19 2010-02-17 Método para obter uma solução purificada de polipeptídeos de neurotoxina processados e composição BRPI1008885B1 (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US20798909P 2009-02-19 2009-02-19
EP09153226 2009-02-19
US61/207,989 2009-02-19
EP091532267 2009-02-19
US27517309P 2009-08-26 2009-08-26
EP09168679 2009-08-26
EP091686790 2009-08-26
US61/275,173 2009-08-26
PCT/EP2010/000985 WO2010094463A1 (en) 2009-02-19 2010-02-17 Means and methods for manufacturing highly pure neurotoxin

Publications (2)

Publication Number Publication Date
BRPI1008885A2 true BRPI1008885A2 (pt) 2016-03-15
BRPI1008885B1 BRPI1008885B1 (pt) 2021-09-28

Family

ID=42084499

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1008885-7A BRPI1008885B1 (pt) 2009-02-19 2010-02-17 Método para obter uma solução purificada de polipeptídeos de neurotoxina processados e composição

Country Status (12)

Country Link
US (2) US9447175B2 (pt)
EP (1) EP2398824B1 (pt)
JP (1) JP5795539B2 (pt)
KR (1) KR101806567B1 (pt)
CN (1) CN102325792B (pt)
AU (1) AU2010214834B2 (pt)
BR (1) BRPI1008885B1 (pt)
CA (1) CA2751311C (pt)
IL (1) IL214372A0 (pt)
MX (1) MX340772B (pt)
RU (1) RU2571212C2 (pt)
WO (1) WO2010094463A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101005853B (zh) * 2004-07-26 2011-05-04 莫茨药物股份两合公司 包含肉毒杆菌神经毒素的治疗组合物
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US9161970B2 (en) * 2007-12-12 2015-10-20 Allergan, Inc. Dermal filler
US8663942B2 (en) * 2009-04-27 2014-03-04 Merz Pharma Gmbh & Co. Kgaa Means and methods for the determination of the amount of neurotoxin polypeptide and of its catalytic and proteolytic activities
WO2011048044A1 (en) * 2009-10-21 2011-04-28 Merz Pharma Gmbh & Co. Kgaa System for determining unprocessed and partially processed neurotoxin type a
US10087432B2 (en) 2012-11-21 2018-10-02 Ipsen Bioinnovation Limited Methods for the manufacture of proteolytically processed polypeptides
EP3607977A1 (en) * 2013-01-16 2020-02-12 KCI Licensing, Inc. Ion exchange enhanced absorbent systems
US20170128551A1 (en) * 2014-06-13 2017-05-11 Klaus Fink Novel uses of recombinant clostridial neurotoxins with decreased duration of effect
GB201517450D0 (en) * 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
EP3263710A1 (en) * 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
RU2762607C2 (ru) 2016-09-13 2021-12-21 Аллерган, Инк. Стабилизированные небелковые композиции клостридиального токсина

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU641178B2 (en) 1989-08-16 1993-09-16 Cetus Oncology Corp Prohormone cleavage site blocking antibody
US6667158B1 (en) * 1998-12-17 2003-12-23 The United States Of America As Represented By The Secretary Of The Army Antibodies against type a botulinum neurotoxin
US20090018081A1 (en) * 1999-08-25 2009-01-15 Allergan, Inc. Activatable clostridial toxins
GB9921592D0 (en) * 1999-09-13 1999-11-17 Microbiological Res Authority Preparation of highly pure toxin fragments
US6678651B2 (en) 2000-09-15 2004-01-13 Mindspeed Technologies, Inc. Short-term enhancement in CELP speech coding
CA2428270C (en) 2000-11-06 2013-07-02 Leonard A. Smith Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
ATE541047T1 (de) 2002-08-01 2012-01-15 Univ California Therapeutische monoklonale antikörper zur neutralisierung von botulinum neurotoxinen
RU2230325C2 (ru) * 2002-08-15 2004-06-10 Научно-исследовательский институт микробиологии Министерства обороны Российской Федерации Способ приготовления очищенного препарата ботулинического токсина типа а
US20080171347A1 (en) * 2003-04-11 2008-07-17 Atassi M Zouhair Determining and reducing immunoresistance to botulinum toxin therapy using botulinum toxin a peptides
CN101005853B (zh) * 2004-07-26 2011-05-04 莫茨药物股份两合公司 包含肉毒杆菌神经毒素的治疗组合物
DE102005002978B4 (de) * 2005-01-21 2013-04-25 Merz Pharma Gmbh & Co. Kgaa Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
WO2008013797A2 (en) 2006-07-24 2008-01-31 The Cleveland Clinic Foundation Compositions and methods for macular degeneration
JP2008113592A (ja) * 2006-11-02 2008-05-22 Biseibutsu Kagaku Kenkyusho:Kk クロストリジウム・パーフリンゲンスの産生する新規な毒素
EP2048156A1 (en) * 2007-10-12 2009-04-15 Merz Pharma GmbH & Co.KGaA Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin
JP2010528999A (ja) * 2007-06-01 2010-08-26 メルツ・ファルマ・ゲーエムベーハー・ウント・コ・カーゲーアーアー ボツリヌストキシンの神経毒成分に基づいた、温度安定な筋弛緩薬を固体形態で供給する方法
US7732579B2 (en) 2007-06-13 2010-06-08 The United States Of America As Represented By The Secretary Of Agriculture High-affinity monoclonal antibodies for botulinum toxin type A
WO2009014854A1 (en) * 2007-07-26 2009-01-29 Allergan, Inc. Methods of activiting clostridial toxins

Also Published As

Publication number Publication date
KR20110122852A (ko) 2011-11-11
AU2010214834A1 (en) 2011-08-18
RU2011138060A (ru) 2013-03-27
AU2010214834B2 (en) 2016-04-14
BRPI1008885B1 (pt) 2021-09-28
CN102325792B (zh) 2018-01-09
JP5795539B2 (ja) 2015-10-14
EP2398824A1 (en) 2011-12-28
KR101806567B1 (ko) 2018-01-10
IL214372A0 (en) 2011-09-27
MX340772B (es) 2016-07-26
JP2012518018A (ja) 2012-08-09
RU2571212C2 (ru) 2015-12-20
WO2010094463A1 (en) 2010-08-26
CA2751311A1 (en) 2010-08-26
MX2011008759A (es) 2011-09-09
US9447175B2 (en) 2016-09-20
CN102325792A (zh) 2012-01-18
EP2398824B1 (en) 2018-12-26
US20160340417A1 (en) 2016-11-24
US9963502B2 (en) 2018-05-08
US20120004179A1 (en) 2012-01-05
CA2751311C (en) 2019-08-06

Similar Documents

Publication Publication Date Title
BRPI1008885A2 (pt) anticorpo, método para a produção de um anticorpo, uso do anticorpo, método para a produção de polipeptídeo de neurotoxina processado, métoro para a produção de um medicamento e composição
BR112015002091A2 (pt) método para a produção de um polipeptídeo, polipeptídeo, uso de um polipeptídeo e composição
BRPI1014253A2 (pt) polinucleotídeo codificado um polipeptídeo de neurotoxina, vetor, célula hospedeira, anticorpo, uso de um polinucleotídeo, método para a fabricação de um polipeptídeo de neurotoxina e método para a fabricação de um medicamento
BR112012000296A2 (pt) composição e método para produção de um propante cerâmico ultraleve.
BR112014016047A8 (pt) composição de compósito degradável, composição, e método de uso um compósito degradável
BRPI1005322A2 (pt) anticorpo, composição farmacêutica e uso de pelo menos um anticorpo
BR112015007120A2 (pt) anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo
BR112015006824A2 (pt) anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico
BR112014012624A2 (pt) anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo
BR112014003802A2 (pt) composto, composto composição farmacêutica, uso de um composto, método para fabricar um composto, e, preparação de um medicamento
BRPI1006141A2 (pt) composições de anticorpo modificado, métodos para preparar e usar as mesmas
CL2011002943A1 (es) Anticuerpo triespecifico o tetraespecifico; metodo para la preparacion de dicho anticuerpo; celula huesped; composicion farmaceutica.
BR112013023653A2 (pt) anticorpo biespecífico, método de preparação do anticorpo, e composição farmacêutica
BRPI1007867A2 (pt) anticorpos para troponina i e método s de uso para os mesmos
BRPI1008971A2 (pt) métodos para preparar uma proteína biológica condicionalmente ativa, e um modificador de resposta biológica condicionalmente ativo, proteína biológica condicionalmente ativa, e, composição farmacêutica
BR112012026570A2 (pt) composto, composição farmacêutica, uso de um composto, método para o tratamento de um indíviduo e produto combinado
BR112013030163A2 (pt) composto, uso cosmético de pelo menos um composto, composição farmacêutica ou cosmética e processo para preparar um composto.
BR112014001346A2 (pt) composto nanotransportador, método, composto farmacêutico e uso de um composto
BR112012025375A2 (pt) compósito absorvente, artigo de cuidade pessoal absorvente e método para preparação de um artigo de cuidado pessoal absorvente
BR112015002263A2 (pt) polipeptídeo de fusão, polipeptídeo de fusão dimérico, método para a produção de um receptor fc solúvel, uso de um polipeptídeo de fusão imobilizado e composição farmacêutica
BRPI1008145A2 (pt) proteína de ligação de antígeno biespecífico, método para preparação de uma proteína de ligação de antígeno biespecífico, célula hospedeira, composição farmacêutica, uso da proteína de ligação de antígeno biespecífico e método para o tratamento de um paciente.
BR112012022878A2 (pt) composto, composição farmacêutica, uso do compostos e método de tratamento
BR112013006092A2 (pt) laminado, matéria-prima do laminado, método para preparação de um laminado e uso do laminado
BR112012022879A2 (pt) composto, composição farmacêutica, uso do composto e método de tratamento
BR112012001998A2 (pt) solução oftálmica, uso de um composto, e, método para preparação de uma solução oftálmica.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/02/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.